Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.50 |
| ▸ | PPARA | Q07869 | 8/20 | 0.48 |
| ▸ | PPARG | P37231 | 7/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL979145 | 0.89 | KDM4E (0.65) | KDM4EHRH3PPARAPPARGNPC1 | |
| SCHEMBL4888378 | 0.86 | RAB9A (0.62) | KDM4EHRH3PPARAPPARGNPC1 | |
| SCHEMBL4887665 | 0.84 | RAB9A (0.42) | KDM4EHRH3PPARAPPARGNPC1 | |
| SCHEMBL5015708 | 0.84 | POLB (0.52) | THRB | |
| SCHEMBL5204314 | 0.82 | KDM4E (0.54) | KDM4EHRH3PPARAPPARGNPC1 | |
| SCHEMBL3532628 | 0.81 | KDM1A (0.57) | KDM4EHRH3PPARAPPARGNPC1 | |
| SCHEMBL3376008 | 0.81 | KDM4E (0.59) | KDM4EHRH3PPARAPPARGNPC1 | |
| SCHEMBL5226577 | 0.80 | C1R (0.45) | KDM4EHRH3PPARAPPARGPPARD | |
| SCHEMBL5022312 | 0.80 | KDM4E (0.61) | KDM4EHRH3PPARAPPARGNPC1 | |
| SCHEMBL3530493 | 0.79 | RAB9A (0.53) | KDM4EHRH3PPARAPPARGNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446127-B2 | Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders | SK HOLDINGS CO, LTD. (KR) | 2008-11-04 | — | — | US | disclosed |
| US-20050107371-A1 | Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107371-A1 | Chroman carboxylic acid derivatives for the treatment of diabetes and lipid disorders | GPR119, CEL, ACACA | KDM4E 2330/4885HRH3 3441/4885PPARA 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.